ERβ augmented the downstream TCR signaling cascade, and the combined use of ERβ agonist and anti-PD-1 substantially increased tumor-infiltrating CD8+ T cells and sensitized various syngeneic tumors to ICI immunotherapy in mice18. Here, ESR2 is linked to neoplasm.